Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PH94B intranasal · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| PH94B intranasal spray | EXPERIMENTAL | - |
| Placebo intranasal spray | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| PH94B intranasal spray | DRUG | Comparison of PH94B single dose intranasal spray and Placebo single dose intranasal spray |
Inclusion Criteria: * Subject currently meets the Diagnosis of Social Phobia as defined in Diagnostic and Statistical Manual of Mental Disorders, 4th Edition which is not secondary to another pre-existing psychiatric condition or to a medical condition. * Liebowitz Social Anxiety Scale (LSAS) score...
PH94B intranasal is an investigational small molecule being developed for the treatment of social phobia, also known as social anxiety disorder. It is administered intranasally and is currently in Phase 2 clinical development. The drug is not yet approved and remains under investigation for this psychiatric condition.
PH94B intranasal is being developed by Vistagen Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol VTGN. The company is conducting clinical research on this intranasal small molecule for the treatment of social phobia and social anxiety disorder.
PH94B intranasal is in Phase 2 clinical development. A Phase 2 clinical trial has been completed, and the drug remains investigational. It has not received FDA approval and is still being studied for its safety and efficacy in treating social phobia and social anxiety disorder.
PH94B intranasal has one completed Phase 2 clinical trial registered as NCT01217788, titled "Intranasal PH94B for Management of the Symptoms of Generalized Social Phobia." This randomized, double-blind, placebo-controlled trial enrolled 90 participants in the United States, with a minimum age of 18 years.
PH94B intranasal refers to the intranasal formulation of the drug PH94B. The clinical trial NCT01217788 investigates this intranasal form for the management of symptoms of generalized social phobia. The drug is being developed by Vistagen Therapeutics under the ticker VTGN.